

# OUR COMMITMENT TO ACCESS

Throughout our history, Mylan's foundation and core business model have been focused on providing access to medicine. Given the significance of patient needs across the globe and across all income levels, we are convinced that meeting this challenge requires a consistent and sustainable commitment. To reinforce that commitment, we have developed access objectives and key performance indicators (KPIs) that flow from our mission statement and seek to describe how we have and will continue to operate universally to fulfill our aim of providing high quality medicines to billions of patients around the world.



## OUR MISSION

At Mylan, we are committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we:

- Innovate to satisfy unmet needs
- Make reliability and service excellence a habit
- Do what's right, not what's easy
- Impact the future through passionate global leadership

## OUR ACCESS OBJECTIVES:

Continuously leverage the breadth, depth and capability of our business model to consistently provide high quality medicine and related services to meet the needs of patients in low-, middle- and high-income countries

Research and develop new dosage forms that will improve effective adherence; alternative product options that will provide more affordable access; and opportunities to bring our existing portfolio to additional countries and regions

Cultivate quality-focused internal and external manufacturing capabilities and services along with pricing approaches that allow for both affordable patient access and sustainable supply

Apply the same commercial and operational focus as well as commitment to quality and safety while supplying products to patients and countries with varying degrees of income level and resources

Seek out opportunities to provide access-related industry and global public health leadership

## OUR ACCESS KPIs:

- Doses sold
- Number of products
- Number of countries and territories reached
- Therapeutic categories
- Coverage percentage of the top ten causes of death globally
- Coverage percentage of the top ten causes of death across low- and lower-middle income countries

- Products in development by region
- Products pending approval by region

- Types of products
- Average selling price of Mylan's medicines
- Customer service levels globally and by region

- Percentage of low- and lower-middle income countries reached
- Doses sold in low- and lower-middle income countries
- Number of products on the World Health Organization's (WHO) Essential Medicines List
- Number of products on the WHO list of prequalified products (including cross-listed approvals)

- Active partnerships or organizational memberships related to increasing access to medicines